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Abstract
Background: Hepatitis B vaccine adjuvant, alum, is generally used for vaccination although it does not stimulate
Th1 immunity and 10% of the population has low or no antibody response. Efforts have been continued to find
more efficient vaccine adjuvants for better antibody response as well as stimulation of Th1 immunity.
Methods: CpG DNA was used as an adjuvant for recombinant HBsAg to immunize 6- to 8-week-old female BALB/c
mice with or without alum for different dosages. The production of HBsAb, CD80 and CD86 from dendritic cells,
and cytokines IL-10, IL12, etc., were analyzed and compared for the performance of immunization.
Results: 5-20 μg CpG DNA had the best co-stimulation effect of HBsAb serum conversion for mice vaccinated with
recombinant expressed HBsAg. The mice vaccinated with recombinant 20 μg CpG DNA and regular vaccine
(containing alum adjuvant) had the highest concentration of antibody production. IL-12b, IL-12a and IL10 mRNA
reached to the peak level between 3 and 6 hours after the CpG DNA induction in splenocytes. The expression
levels of CD80 and CD86 leucocyte surface molecules were increased with 20 μg CpG DNA alone or with 20 μg
CpG DNA and 4 μg HBsAg.
Conclusions: Our results confirmed the adjuvant effect of CpG DNA for HBsAg in the mouse model. The increase
of IL10 and IL12 production suggested the involvement of Th1 cell activation. The activation of CD80 and CD86
molecules by CpG-ODN might be part of the mechanism of T/B cells coordination and the enhancement of
recombinant HBsAg induced immune response.
Background
Hepatitis B (HB) is the disease caused by hepatitis B
virus (HBV) infection and is the most commonly seen
liver disease worldwide [1]. The virus can be transmitted
parenterally, perinatally and sexually [2,3]. The viral
infection has a worldwide distribution. The World
Health Organization estimates that more than 2 billion
people have been infected with HBV worldwide, 360
million of which are chronically infected and at risk of
liver cirrhosis, liver cancer or other serious illness, or
death. HBV is estimated to be responsible for 500, 000
to 700,000 deaths annually [4]. A survey study
conducted by China CDC showed 7.2% weighted surface
antigen (HBsAg) prevalence by ELISA among popula-
tion aged 1~59 years old in 2006 [5].
Despite the progress in prophylaxis, diagnosis and
treatment, vaccination is still the most cost effective way
of fighting against the virus. The currently used recombi-
nant HBsAg has to be combined with adjuvant, usually
alum, due to the weak immunity production of the anti-
gen alone. Alum has been used as vaccine adjuvant for
more than 70 years, although the molecular mechanism
of action and the target cells of alum are still unknown.
It has been assumed that adsorption to alum increases
antigen availability at the injection site, allowing an effi-
cient uptake by antigen-presenting cells (APCs) [6]. The
increased antigen uptake by dendritic cells (DCs)
observed in vitro also supported the antigen delivery
function [7]. The intraperitoneal (i.p.) injection of alum
could induce the recruitment of monocytes, which may
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any medium, provided the original work is properly cited.uptake the vaccine antigen [8]. Alum is generally recog-
nized as a stimulator of Th2 immunity. However, it does
not stimulate Th1 immunity and 10% of the population
has low response or no antibody response [9].
CpG DNA can induce proliferation of almost all B
cells and trigger polyclonal immunoglobulin (Ig) secre-
tion, which is T cell independent and antigen nonspeci-
fic [10]. A strong synergetic response was observed
when the CpG DNA is used together with alum [11].
We show the dose related enhancement effect of CpG
DNA in increasing the production of HBsAb in mouse
compared with the recombinant antigen of HBsAg alone
or alum adjuvant HBV vaccine. The synergetic response
was also observed in the expression levels of cluster of
differentiation 80 (CD80) and cluster of differentiation
86 (CD86). The dynamics of a group of cytokines was
analyzed and compared for different experiment groups.
Methods
Oligodeoxynucleotides
ODN (BW006) was provided by Yunnan Wosen Bio-
technology Company. BW006 was synthesized with the
sequence of 5’-tcgacgttcgtcgttcgtcgttc-3’ and followed by
sulphurization. Lipopolysaccharide (LPS) level in BW6
was less than 0.5 ng/mg by Limulus assay.
Recombinant HBsAg
The awd2 subtype HBsAg was expressed in Hansenular
polymorpha yeast and produced by Yunnan Wosen Bio-
technology Company. The antigen had a concentration
of 0.236 mg/ml and purity of greater than 99.0% by
high-performance liquid chromatography (HPLC) and
silver staining. LPS level in the antigen was less than
10 EU/ml by Limulus assay.
HB vaccine
The awd2 HB vaccine was made with alum adjuvant and
provided by Yunnan Wosen Biocenology Company. The
concentrations of HBsAg and alum were 24 μg/ml and
0.5 mg/ml respectively.
Reagent for the detection of cytokine expression, anti-
HBs and leucocyte surface molecules
The reagents for cytokine detection were provided by
Panomics Company and used per protocol of each cyto-
kine. The Anti-HBs was detected with automated che-
miluminescent microparticle immunoassay, Abbott
ARCHITECT
® anti-HBs. The reagents for the detection
o fl e u c o c y t es u r f a c em o l e c u l e sw e r ep r o v i d e db yB i o -
Legend Company.
Evaluation of cytokine mRNA
Splenocytes were isolated from 6- to 8-week-old female
BALB/c mouse (H-2
d, National Institute for the Control
of Pharmaceutical and Biological Products, Beijing,
China). Single cell suspensions (1 × 10
6/ml) were pre-
pared with NycoPrep ™ 1.077A (AXIS-SHIELD PoC
AS, Oslo, Norway) and suspended in 1640 medium
(RPMI 1640, Hyclone) with penicillin-streptomycin
(final concentrations of 100 U/ml and 100 μg/ml respec-
tively) (Sigma, Irvine, U.K.). 0.1 ml of the single cell sus-
pension and 0.1 ml BW006 (final concentration of 5 μg/
ml) were added to round-bottom 96 wells microtiter
plates and cultured at 37°C with 5% CO2.T h em R N A
expression of IL-2, IL-4, IL-5, IL-10, IL-12a, IL-12b and
IFN-r were analyzed at 1, 3, 6 and 12 hours respectively,
each in triplicate.
Evaluation of in vivo HBsAb production
100 6- to 8-week-old female BALB/c mice (H-2
d,
National Institute for the Control of Pharmaceutical and
Biological Products, Beijing, China) were evenly divided
into 10 groups and respectively received a single intra-
muscular injection (i.m.) into left tibialis anterior mus-
cles, of 0.1 ml solution containing 50 μga l u m ,2 0μg
BW006, 2 μg recombinant HBsAg, 2 μg recombinant
HBsAg with 1.25 μg BW006, 2 μg recombinant HBsAg
with 5 μg BW006, 2 μg recombinant HBsAg with 20 μg
BW006, 2 μg recombinant HB vaccine, 2 μg recombinant
HB vaccine with 1.25 μg BW006, 2 μg recombinant HB
vaccine with 5 μg BW006 and 2 μg recombinant HB vac-
cine with 20 μg BW006. The duplicate aliquots of plasma
were collected weekly from 1-4 weeks, one for HBsAb
testing and the other one for HBsAb titration if it
was HBsAb positive. The antibodies against HBsAg
were detected and quantified in triplicate for each speci-
men with Abbott ARCHITECT
® anti-HBs reagent as
described above. The average value of the triplicate equal
to or greater than 10 mIU/ml was considered as positive
HBsAb conversion. The numbers of serum HBsAb con-
version and titer of each positive serum were calculated.
Detection of leucocyte surface molecules CD80 and CD86
Sixteen 6- to 8-week-old female BALB/c mice (H-2
d,
National Institute for the Control of Pharmaceutical and
Biological Products, Beijing, China) were evenly divided
into 4 groups and given a single subcutaneous injection
of 0.1 ml solution containing 4 μg recombinant HBsAg,
20 μg BW006, 4 μgr e c o m b i n a n tH B s A gw i t h2 0μg
BW006, or NS, respectively. The mice of all four groups
were euthanized 12 hours after the injection and dendri-
tic cells were separated by auto-MACs kit (Miltenyibiotec
Com.) per manufacturer’s instructions. Single cell sus-
pensions (1 × 10
6/ml) were prepared with NycoPrep ™
1.077A (AXIS-SHIELD PoC AS, Oslo, Norway). Cell con-
centration of dendritic cells were adjusted to 1 × 10
5/ml
and co-culvated with rat-anti mouse APC-CD11c, CD80-
FITC and CD86-PE antibodies from BioLegend company
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trifuged at 400 g for 10 minutes and re-suspended with
500 μl of 10% paraformaldehyde. The expression levels of
the surface molecules CD80 and CD86 were detected
and quantified by flow cytometry.
Statistical analysis
Statistical analysis was performed by SAS version 9.2
(SAS Institute Inc., Cary, North Carolina, USA). Catego-
rical variables were compared by Chi’ss q u a r et e s t .I f
50% of cells had expected counts less than 5, Fisher’s
Exact test results would be used. Continuous variables
were expressed as mean with standard deviation and
compared by Student’s t-test or Mann Whitney U test
as appropriate. All statistical tests were two-sided, and p
values less than 0.05 were considered statistically
significant.
Results
Enhancement of HBsAb production
HBsAb serum conversion was confirmed after 3 weeks
of vaccination in all 10 mice injected with 20 μg BW006
(CpG DNA) and HBV vaccine, while 6 and 8 mice
respectively had HBsAb serum conversion after 3 and
4 weeks of vaccination with regular HBV vaccine alone.
The positive proportion of HBsAb serum conversion
was significantly higher after two weeks of vaccination
in the group vaccinated with 20 μgB W 0 0 6a n dH B V
vaccine than that in the group with HBV vaccine alone
(7 Vs. 1 out of 10, P = 0.0198). BW006 dose dependant
co-stimulation effect of HBsAb serum conversion on
HBV vaccine was seen between the ranges of 1.25 μgt o
20 μg. The result showed that 5 μg BW006 had the best
co-stimulation effect of HBsAb serum conversion for
mice vaccinated with recombinant expressed HBsAg. All
10 mice vaccinated with HBsAg and 5 μg BW006 had
anti-HBs serum conversion after 3 weeks. Surprisingly,
5 μg BW006 with HBsAg had almost the same co-
stimulation effect on HBsAb serum conversion as 20 μg
BW006 with HBV vaccine in the mouse model. How-
ever, the fourth week HBsAb concentration was at least
2 times higher in the mice vaccinated with 20 μg
BW006 with vaccine than that in any other combination
(Figure 1).
Increase of cytokines mRNA production of splenocytes
with stimulation of BW006
Splenocytes co-cultured with 5 μg/ml final concentra-
tion of BW006 had different effects on cytokines pro-
duction (Figure 2). The highest increase of cytokines
was IL-12b between 3 and 6 hours after the introduc-
tion of BW006 (22.29 and 26.07 times vs. 0 hour, P <
0.0001, respectively). The peak increase of IL-12b began
decreasing after 6 hours of co-culture with BW006 and
h a da l m o s th a l ft h ep e a kv a l u eo fm R N Aa t1 2h o u r s .
IL-12a increased significantly after 2 hours of stimula-
tion. However, the mRNA production was only 2.17
times high as the value before co-culture with BW006
and decreased to the original value around 6 hours. The
other significant increase of cytokine mRNA was
observed in IL-10, which had a peak increase between 3
and 6 hours (10.86 and 11.93 times vs. 0 hour, P <
0.0001, respectively) and decreased to almost half at 12
hours. All the other cytokines tested, including IL-2,
IL-4, IL-5 and IFN-r, had variations during the observa-
tion period. But these differences were not significant.
Figure 1 The average production of HBsAb (mIU/ml) in mice
immunized with different dosage of CpG DNA and
recombinant expressed HBsAg or HBV commercial vaccine in
four weeks. A: mice immunized with HBV vaccine and 20 μg CpG
DNA; star: mice immunized with HBV vaccine and 5 μg CpG DNA;
dot: mice immunized with HBsAg and 5 μg CpG DNA; square: mice
immunized with HBsAg and 20 μg CpG DNA; diamond: mice
immunized with HBV vaccine and 1.25 μg CpG DNA; circle: mice
immunized with HBsAg and 1.25 μg CpG DNA; triangle: mice only
immunized with HBV vaccine; line only: mice only immunized with
HBsAg; mice injected with alum and saline solution did not produce
HBsAb.
Figure 2 The ratios of IL-2, IL-4, IL-5, IL-10, IL-12a, IL-12b, IFN-r
mRNA expression in mouse mononuclear cells stimulated with
CpG DNA (5 μg/ml) in 12 hours. Line with squares: IL-12b;
triangles: IL-10; dots: IL-12a; circles: IL-2; stars: IL-4; diamonds: IL-5;
line only: IFN-r.
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CD86
There was no significant difference between mice
groups of negative control and 4 μgr e c o m b i n a n t
HBsAg injection in the positive proportion (8.61% Vs.
10.65%) and fluorescent intensity (118.12 Vs. 122.6) of
surface molecule CD80 expression in leucocyte cells
(Figure 3). 20 μg BW006 increased the positive propor-
tion (15.14% for BW006 alone and 15.84% for BW006
and 4 μg recombinant HBsAg) and fluorescent intensity
(139.86 for BW006 alone and 158.67 for BW006 and
4 μg recombinant HBsAg) of surface molecule CD80
expression in leucocyte cells.
The same trend was seen in CD86 (Figure 4), in which
positive expression proportion was almost doubled in
leucocyte cells compared with that in the control group
(52.12% vs. 27.37%) or in 4 μg recombinant HBsAg
injection alone group (54.09% vs. 28.36%). The fluores-
cent intensity of surface molecule CD86 expression also
increased with BW006 compared with that of the con-
trol group (292.68 Vs. 213.78) or of HBsAg alone group
(299.35 Vs. 211.78) in leucocyte cells.
Discussion
Alum adjuvant HBV vaccine has been used for hepatitis
B prevention for decades. However, there have been vac-
cine unresponsive cases reported in the immunodeficient
patients of uremia and other conditions [11-13]. Scien-
tists have been working for applicable new adjuvant for
HBV and other diseases [14-17]. CpG ODN can enhance
the immune response of live-attenuated or multivalent
vaccines that cannot mix with alum. There have been
studies that confirmed the potentiality of CpG ODN as
HBV adjuvant [10,18]. We designed the new sequence of
CpG ODN with two motifs that could improve the
immune response of HBV recombinant expressed HBsAg
and also vaccine (containing alum adjuvant). The co-sti-
mulatory effect was observed dynamically with anti-HBs
production in mice. The production of cytokines in vitro
and the expression of leucocyte surface molecules CD80
and CD86 were evaluated in vitro for the possible
mechanism of the enhanced immunization of HBV.
Our new CpG ODN alone can induce HBsAg produ-
cing anti-HBs response or together with alum in the
mouse model (CpG ODN and regular vaccine groups).
However, a stronger specific antibody production was
observed in the mice immunized with CpG ODN and
HBV regular vaccine after 3 weeks of vaccination, owing
to the synergistic action of CpG and alum. Alum adju-
vant has an important disadvantage of induction of a
Th2 rather than a Th1-type immune response. The use
of alum as an adjuvant was reported to interfere with
cell-mediated immunity and blocks activation of CD8+
CTL [19]. The Th1 immune response induced by CpG
ODN was able to overcome the Th2 bias of alum for
both antibody isotype and CTL response when both the
agents were used together [20]. Our results showed even
higher specific antibody production.
Interleukin-12, a cytokine with an important role
against intracellular pathogens, promotes Th1 cell devel-
opment, cell mediated cytotoxicity, and interferon-
gamma production. The production of IL12, especially
the increase of IL-12b played an important role in HBV
clearance [21]. Almost a 30-fold increase of IL12b was
observed in splenocytes after 3-6 hours co-culture with
5 μg/ml final concentration of CpG ODN. The signifi-
cant increase of IL10 seems to play a role in Th1/Th2
cells balance.
Figure 3 The positive proportions (%) of CD80 (bar) and the
average fluorescent intensities (line) of mouse DC cells
stimulated with saline solution (group 1), 4 μg HBsAg (group
2), 20 μg CpG DNA (group 3) and 4 μg HBsAg+20 μg CpG DNA
(group4), respectively.
Figure 4 The positive proportions (%) of CD86 (bar) and the
average fluorescent intensities (line) of mouse DC cells
stimulated with saline solution (group 1), 4 μg HBsAg (group
2), 20 μg CpG DNA (group 3) and 4 μg HBsAg+20 μg CpG DNA
(group 4), respectively.
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signals delivered through one or more receptors on the
surface of T cells. The proteins, CD80 and CD86 (also
known as the B7-1 and B7-2 ligands), are molecules
found on activated B cells and monocytes, which pro-
vide a costimulatory signal necessary for T cell activa-
tion and survival [22,23]. The expression of CD80 and
CD86 has been used for evaluation of T cell response
for vaccine development [24-26]. The increased produc-
tion of HBsAb as well as IL12 and IL10 might be asso-
ciated with the activation of CD80 and CD86 expression
in the experiment groups with HBsAg and CpG-ODN.
Decreased function of peripheral blood dendritic cells
has been reported in patients with hepatocellular carci-
noma with hepatitis B and C virus infection [27]. Mye-
loid dendritic cells (mDC) of patients with chronic HBV
are impaired in their maturation and function, resulting
in more tolerogenic rather than immunogenic responses,
which may contribute to viral persistence [28]. It is
interesting that there was no significant difference in
positive proportion or intensity of CD80 and CD86
expression between the mouse group vaccinated with
CpG-ODN alone and the group with CpG-ODN
together with recombinant HBsAg in our experiment.
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